CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound that potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB. It restores hypertension (MAP), increases Nrf2 and the expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis, and inflammation in chronic kidney disease (CKD) rats. For research use only, not for sale to patients.
- Potently activates Nrf2.
- Inhibits the pro-inflammatory transcription factor NF-κB.
- Attenuates activation of NF-κB and transforming growth factor-β pathways.
- Reduces glomerulosclerosis, interstitial fibrosis, and inflammation in chronic kidney disease (CKD) rats.
- Upregulates expression of antioxidant enzymes.
- Protects pancreatic tissue and exhibits anti-inflammatory activity.